← Back to Search
Vault Particles: A New Generation Of Delivery Nanodevices.
A. Casañas, P. Guerra, I. Fita, N. Verdaguer
Published 2012 · Computer Science, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Vault particles possess many attributes that can be exploited in nanobiotechnology, particularly in the creation of drug delivery nanodevices. These include self-assembly, 100 nm size range, a dynamic structure that may be controlled for manipulation of drug release kinetics and natural presence in humans ensuring biocompatibility. The flexibility and the adaptability of this system have been greatly enhanced by the emerging atomic-level information and improved comprehension of vault structure and dynamics. It seems likely that this information will allow their specific tailoring to the individual requirements of each drug and target tissue. These properties provide vaults with an enormous potential as a versatile delivery platform.
This paper references
Vault nanoparticles containing an adenovirus-derived membrane lytic protein facilitate toxin and gene transfer.
Cheng-Yu Lai (2009)
Artificial viruses: a nanotechnological approach to gene delivery
Enrico Mastrobattista (2006)
A Vault Nanoparticle Vaccine Induces Protective Mucosal Immunity
C. Champion (2009)
The Major Vault Protein Is a Novel Substrate for the Tyrosine Phosphatase SHP-2 and Scaffold Protein in Epidermal Growth Factor Signaling*
S. Kolli (2004)
Vault ribonucleoprotein particles: sarcophagi, gondolas, or safety deposit boxes?
K. Suprenant (2002)
Utilization of a protein "shuttle" to load vault nanocapsules with gold probes and proteins.
Lisa E Goldsmith (2009)
The 193-Kd Vault Protein, Vparp, Is a Novel Poly(Adp-Ribose) Polymerase
V. Kickhoefer (1999)
Vaults and Telomerase Share a Common Subunit, TEP1*
V. Kickhoefer (1999)
The drug resistance-related protein LRP is the human major vault protein
G. Scheffer (1995)
Reversible pH lability of cross-linked vault nanocapsules.
M. Yu (2008)
Assembly of Vault-like Particles in Insect Cells Expressing Only the Major Vault Protein*
A. G. Stephen (2001)
Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA
N. Kedersha (1986)
Interaction of Vault Particles with Estrogen Receptor in the MCF-7 Breast Cancer Cell
C. Abbondanza (1998)
Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes
Mikael C Herlevsen (2007)
The mechanism of vault opening from the high resolution structure of the N-terminal repeats of MVP
Jordi Querol-Audí (2009)
Nanoparticles in cancer therapy and diagnosis.
I. Brigger (2002)
Cryoelectron microscopy imaging of recombinant and tissue derived vaults: localization of the MVP N termini and VPARP.
Y. Mikyas (2004)
Vaults are dynamically unconstrained cytoplasmic nanoparticles capable of half vault exchange.
J. Yang (2010)
Vault nanocapsule dissociation into halves triggered at low pH.
Lisa E Goldsmith (2007)
Vaults are the answer, what is the question?
V. Kickhoefer (1996)
The vault exterior shell is a dynamic structure that allows incorporation of vault-associated proteins into its interior.
Michael J Poderycki (2006)
Vault ribonucleoprotein particles from rat and bullfrog contain a related small RNA that is transcribed by RNA polymerase III.
V. Kickhoefer (1993)
Peptide and protein drug delivery to and into tumors: challenges and solutions.
V. Torchilin (2003)
Structural stability of vault particles.
R. Esfandiary (2009)
Targeting vault nanoparticles to specific cell surface receptors.
V. Kickhoefer (2009)
PTEN Associates with the Vault Particles in HeLa Cells*
Z. Yu (2002)
Structure of the vault, a ubiquitous celular component.
L. B. Kong (1999)
Engineering of vault nanocapsules with enzymatic and fluorescent properties.
V. Kickhoefer (2005)
Vaults and the major vault protein: Novel roles in signal pathway regulation and immunity
W. Berger (2008)
Novel CCL21-Vault Nanocapsule Intratumoral Delivery Inhibits Lung Cancer Growth
U. Kar (2011)
Encapsulation of semiconducting polymers in vault protein cages.
B. Ng (2008)
The Structure of Rat Liver Vault at 3.5 Angstrom Resolution
H. Tanaka (2009)
This paper is referenced by
Protein based therapeutic delivery agents: Contemporary developments and challenges.
Liming Yin (2017)
Polypeptides and Engineered Proteins
Xinyu Liu (2017)
Protein nanoparticles for therapeutic protein delivery.
L. Herrera Estrada (2015)
Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP)
C. Lehuédé (2018)
Role of the PduL enzyme in the function of primitive bacterial organelles found in Salmonella
Y. Liu (2014)
Mechanical stability and reversible fracture of vault particles.
A. Llauró (2014)
Self-healing biomaterials : from molecular concepts to clinical applications
M. Diba (2018)
Ferritin Assembly Revisited: A Time-Resolved Small-Angle X-ray Scattering Study.
D. Sato (2016)
Advancements in prophylactic and therapeutic nanovaccines
P. Bhardwaj (2020)
Decrease in pH destabilizes individual vault nanocages by weakening the inter-protein lateral interaction
A. Llauró (2016)
Cellular factories for coenzyme Q10 production
S. T. H. Lee (2017)
Design and designability of protein-based assemblies.
J. Zhang (2014)
Encapsulins: microbial nanocompartments with applications in biomedicine, nanobiotechnology and materials science.
Tobias W. Giessen (2016)